The US FDA's new biosimilar information campaign does not tackle the non-medical switching controversy, but does attempt to dispel concerns about the difference between biosimilar and interchangeable products.
The effort, targeted at health care providers, is an attempt to answer questions about biosimilars and interchangeable products, including approval...






